GO2 for Lung Cancer first secured a congressional appropriation of $20M in 2008 for fiscal year 2009 to fund the Lung Cancer Research Program (LCRP) to conduct innovative, lung cancer research.

The LCRP is within the Congressionally Directed Medical Research Programs administered by the Department of Defense.

**LCRP VISION:** To eradicate deaths and suffering from lung cancer to better the health and welfare of Service Members, Veterans and the general public.

**LCRP MILITARY RELEVANCE:** The LCRP seeks to support research that is relevant to the healthcare needs of military Service Members, Veterans and their families.

- 900,000 Veterans remain at risk for lung cancer due to age, smoking and other environmental exposures during and after military service.
- Over 26,000 individuals a year have outpatient or hospitalizations within the MHS due to lung cancer.
- There are over 45,000 bed days per year within the MHS for lung cancer, and over 270,000 outpatient encounters per year within the MHS for lung cancer.

**FUNDING HISTORY**

Over its 13-year history, the LCRP funding has fluctuated from year to year, affecting its ability to fund only 30% of research proposals rated excellent or outstanding by reviewers. This bar graph shows the program’s funding from 2009 to 2022, totaling $200.5M since its inception.
Congress must answer the call to action for lung cancer, the leading cause of cancer deaths in the U.S. Increase federal funding to $60M in FY24!

Source: https://cdmrp.army.mil/lcrp/

RESEARCH PORTFOLIO

The pie chart displays the LCRP portfolio from FY09-FY21, based on the program’s areas of emphasis, investment in terms of dollars, percentage of funding and number of awards made for each.

**Dollars Invested per Area of Emphasis (FY09-FY20)**

- **Lung cancer care delivery:** $1,056,306; 0.8%; 3 Awards
- **Screening and early detection:** $41,220,853; 30.5%; 64 Awards
- **Molecular mechanisms of initiation and progression:** $32,477,514; 24.1%; 90 Awards
- **Prevention of occurrence:** $1,606,294; 1.2%; 6 Awards
- **Prevention of recurrence or metastases:** $3,647,642; 2.7%; 10 Awards
- **Treatment:** $31,849,118; 23.6%; 77 Awards
- **Mechanisms of resistance to treatment:** $14,646,636; 10.9%; 38 Awards
- **Predictive markers to assist therapeutic decision-making:** $8,280,469; 6.1%; 20 Awards
- **Non-tobacco contributors to lung cancer development:** $169,500; 0.1%; 1 Award
- **Lung cancer care delivery:** $1,056,306; 0.8%; 3 Awards
- **Screening and early detection:** $41,220,853; 30.5%; 64 Awards
- **Molecular mechanisms of initiation and progression:** $32,477,514; 24.1%; 90 Awards
- **Prevention of occurrence:** $1,606,294; 1.2%; 6 Awards
- **Prevention of recurrence or metastases:** $3,647,642; 2.7%; 10 Awards
- **Treatment:** $31,849,118; 23.6%; 77 Awards
- **Mechanisms of resistance to treatment:** $14,646,636; 10.9%; 38 Awards
- **Predictive markers to assist therapeutic decision-making:** $8,280,469; 6.1%; 20 Awards
- **Non-tobacco contributors to lung cancer development:** $169,500; 0.1%; 1 Award

**Total Investment:** $134.95M; **Total Awards:** 309